Rossari Biotech Limited Posts Steady Q1 FY27 Growth: Net Profit Rises to ₹350.95 Million

Rossari Biotech Limited (CIN: L24100MH2009PLC194818), an ISO 9001:2015, 14001:2015 & 45001:2018 certified company headquartered at Vikhroli (W), Mumbai, has announced its consolidated unaudited financial results for the first quarter of the fiscal year 2026-27 (Q1 FY27) ended June 30, 2026. The financial update highlights solid top-line expansion and sustained net profitability driven by strong volume momentum in operational segments.

Income and Revenue Performance

For the quarter ended June 30, 2026, Rossari Biotech reported a Total Income of ₹7,003.87 million. This marks a robust 28.5% growth year-on-year (YoY) compared to the ₹5,449.16 million generated in the corresponding quarter of the previous fiscal year (Q1 FY26). Sequentially, total income remained highly stable, adjusting fractionally by 0.5% from the ₹7,039.27 million posted in the sequential fourth quarter ended March 31, 2026 (Q4 FY26).

The growth trajectory was primarily led by core operations:

Revenue from Operations: Scaled up significantly by 28.2% YoY to ₹6,972.00 million, up from ₹5,437.16 million in Q1 FY26 and growing sequentially from ₹6,848.62 million in Q4 FY26.

Other Income: Stood at ₹31.87 million for the quarter, compared to ₹12.00 million in Q1 FY26 and ₹190.65 million in Q4 FY26.

Expense Analysis and Operational Efficiency

Total expenses for Q1 FY27 came in at ₹6,531.72 million, compared to ₹4,993.38 million in Q1 FY26 and ₹6,401.98 million in the preceding quarter. The primary driver of expenses was the cost of materials consumed, which stood at ₹5,146.78 million, rising from ₹3,343.99 million in the prior year's parallel quarter due to raw material volume expansion.

A concise view of the remaining operational expenses includes:

Purchase of Stock-in-Trade: ₹146.63 million.

Changes in Inventories: A positive operational impact of ₹(385.16) million due to inventory building, compared to an increase of ₹79.92 million in Q1 FY26.

Employee Benefits Expense: ₹440.44 million, reflecting a measured increase over the ₹374.65 million paid in Q1 FY26.

Finance Costs: Increased to ₹109.77 million against ₹57.28 million in Q1 FY26.

Depreciation and Amortization: ₹256.15 million.

Other Overhead Expenses: Stood at ₹817.11 million.

Profit before accounting for joint ventures, associates, exceptional items, and taxes concluded at ₹472.15 million. After factoring in a share of profit from joint ventures and associates amounting to ₹4.57 million, the profit before tax (PBT) reached ₹476.72 million, marking an annual growth of 3.4% over the ₹460.99 million recorded in Q1 FY26.

Key Earnings and Share Capital Metrics (Q1 FY27)

Consolidated Profit After Tax (PAT): ₹350.95 million (▲ 4.5% YoY)

Total Comprehensive Income: ₹354.46 million (▲ 5.8% YoY)

Paid-up Equity Share Capital: ₹110.78 million (Face Value of ₹2.00 per share)

Basic Earnings Per Share (EPS): ₹6.34 (Up from ₹6.07 in Q1 FY26)

Diluted Earnings Per Share (EPS): ₹6.33 (Up from ₹6.06 in Q1 FY26)

Profitability and Shareholder Returns

Rossari Biotech posted a Consolidated Net Profit After Tax (PAT) of ₹350.95 million for the quarter ended June 30, 2026. This represents an annual growth of 4.5% YoY against the ₹335.96 million recorded in Q1 FY26. Sequentially, profits normalized from the ₹459.67 million achieved in Q4 FY26, in line with seasonal industry dynamics. The entire profit quantum for the period was entirely attributable to the owners of the company, with non-controlling interests registering at nil.

Total tax expenses for the quarter stood at ₹125.77 million, including a current tax charge of ₹161.22 million balanced out by a deferred tax credit of ₹35.45 million.

Accounting for positive adjustments in other comprehensive income-which included exchange differences on translating foreign operations of ₹4.20 million and remeasurements of defined benefit plans-the bank-level Total Comprehensive Income finished at ₹354.46 million, expanding from ₹334.90 million in Q1 FY26. The company's basic EPS rose to ₹6.34, while diluted EPS stood at ₹6.33, strengthening the long-term equity return profile for investors.

Shares of Rossari Biotech Limited was last trading in BSE at Rs. 530.70 as compared to the previous close of Rs. 542.25. The total number of shares traded during the day was 3974 in over 253 trades.

The stock hit an intraday high of Rs. 545.90 and intraday low of 525.05. The net turnover during the day was Rs. 2104386.00.

Source : Equity Bulls

Keywords

RossariBiotech INE02A801020 SpecialtyChemicals Q1FY27 Q1FY2027 ResultUpdate